Moderate Evidence
Research Overview
Follistatin Research for Muscular Dystrophy
An evidence-based overview of research examining Follistatin in the context of muscular dystrophy. This page synthesizes findings from peer-reviewed literature.
Research Summary
AAV1-FS344 gene therapy trials in Becker muscular dystrophy showed 58-125 meter improvements in 6-minute walk distance. This represents the most advanced clinical application of follistatin, though via gene therapy rather than injectable peptide.
Referenced Studies
Click any PMID to view the full study on PubMed.
Other Peptides Studied for Muscular Dystrophy
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. Follistatin may have regulatory approval for some indications but should only be used under qualified medical supervision. Always consult a healthcare provider before making health decisions.